Cargando…
The targeting mechanism of DHA ligand and its conjugate with Gemcitabine for the enhanced tumor therapy
Docosahexaenoic acid (DHA), an omega-3 C22 natural fatty acid serving as a precursor for metabolic and biochemical pathways, was reported as a targeting ligand of anticancer drugs. However, its tumor targeting ability and mechanism has not been claimed. Here we hypothesized that the uptake of DHA by...
Autores principales: | Li, Siwen, Qin, Jingyi, Tian, Caiping, Cao, Jie, Fida, Guissi, Wang, Zhaohui, Chen, Haiyan, Qian, Zhiyu, Chen, Wei R, Gu, Yueqing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4116508/ https://www.ncbi.nlm.nih.gov/pubmed/25004114 |
Ejemplares similares
-
Galactose as Broad Ligand for Multiple Tumor Imaging and Therapy
por: Ma, Yuxiang, et al.
Publicado: (2015) -
Novel harmine derivatives for tumor targeted therapy
por: Li, Siwen, et al.
Publicado: (2015) -
Small Sized EGFR1 and HER2 Specific Bifunctional Antibody for Targeted Cancer Therapy
por: Ding, Li, et al.
Publicado: (2015) -
Pharmacophore Modeling and Virtual Screening for the Discovery of New type 4 cAMP Phosphodiesterase (PDE4) Inhibitors
por: Niu, Miaomiao, et al.
Publicado: (2013) -
Multi-small molecule conjugations as new targeted delivery carriers for tumor therapy
por: Shan, Lingling, et al.
Publicado: (2015)